Analysis of 2 antiapoptotic factors in gliomas: bcl-2 overexpression and p53 mutations

Archives of Pathology and Laboratory Medicine

Volumn 125, Issue 2, 2001, Pages 218-223

  Rodriguez Pereira, C ^a   Suarez Penaranda J M ^a   Barros, F ^a   Sobrido, M J ^a   Vazquez Salvado, M ^a   Forteza, J ^a  

^a HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; ASTROCYTOMA; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; SEQUENCE ANALYSIS;

ADOLESCENT; ADULT; AGED; APOPTOSIS; BRAIN NEOPLASMS; CHILD; FEMALE; GENE EXPRESSION; GENES, P53; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035117143     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
2. Coming to terms with death: Apoptosis in cancer and immune development
3. p53 tumor suppressor gene: From the basic research laboratory to the clinician abridged historical perspective
4. The p53 tumor suppressor gene
5. Biochemical properties of the growth suppressor/oncoprotein p53
6. Immediate early up-regulation of bax expression by p53 but not TGFβ1: A paradigm for distinct apoptotic pathways
7. A model for p53-induced apoptosis
8. P53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma
9. Detection of p53 alterations in human astrocytomas using frozen tissue sections for PCR
10. P53 protein expression in central nervous system tumors: An immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies
11. Paraffin section P53 protein immunohistochemistry in neuroectodermal tumors
12. Expression of the P53 protein in a spectrum of astrocytic tumors
13. P53 immunohistochemical positivity as a prognostic marker in intracranial tumors
14. P53 mutation, expression, and DNA ploidy in evolving gliomas: Evidence for two pathways of progression
15. Prognostic implications of P53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors
16. Cloning of the chromosomal break-point of neoplastic B-cells with the (14-18) chromosome translocation
17. Structure-function analysis of bcl-2 protein. Identification of conserved domains important for homodimerization with bcl-2 and heterodimerization with bax
18. Protooncogene bcl-2 gene transfer abrogates Fas/APO1 antibody-mediated apoptosis of human malignant glioma and confers resistance to chemotherapeutic drugs and therapeutic irradiation
19. Expression of bcl-2 in reactive and neoplastic astrocytes: Lack of correlation with presence or degree of malignancy
20. Human gliomas with wild-type p53 express bcl-2
21. Wild type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T cell lymphoma line
22. Comparison of methods for extracting DNA from formalin-fixed paraffin sections for nonisotopic PCR
23. Simplified methods for silver staining of proteins in polyacrylamide gels and the mechanism of silver staining
24. Bcl-2 protein expression in tumors of the central nervous system
25. Immunohistochemical analysis of bcl-2, bcl-X, Mcl-1 and Bax in tumors of central and peripheral nervous system origin
26. Alterations of the TP53 in human gliomas
27. The relationship between TP53 mutations and overexpression of P53 and prognosis in malignant gliomas of childhood
28. Immunocytochemical detection of p53 in human gliomas
29. Aberrant p53 expression in astrocytic neoplasms of the brain; association with proliferation
30. Analysis of p53 gene mutations in low and high grade astrocytomas by PCR-SSCP and immunohistochemistry
31. Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms
32. Expression of P53 protein, EGFR and proliferating cell antigens in human gliomas
33. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions
34. P53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression
35. Frequency of p53 tumor suppressor gene mutations in human primary brain tumors
36. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value
37. p53 protein in pediatric malignant astrocytomas: A study of 21 patients
38. TP53 alterations and clinical outcome in low grade astrocytomas
39. Comparative study of p53 gene and protein alterations in human astrocytic tumors
40. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products
41. Analysis of p53 gene mutations in human gliomas by PCR-SSCP and DNA sequencing
42. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas
43. Sample preparation and PCR amplification from paraffin-embedded tissues
44. Timing of p53 mutations during astrocytoma tumorigenesis
45. P-TEN: A putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer
46. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
47. Genetic and immunohistochemical analysis of mutant P53 in human breast cancer lines
48. p53 in tumor pathology: Can we trust immunohistochemistry? revisited!
49. p53 in tumor pathology: Can we trust immunocytochemistry?
50. Accumulation of wild type P53 protein in human astrocytomas
51. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas
52. Correlation of P53 immunoreactivity and sequencing in patients with glioma
53. Induction of apoptosis by wild-type p53 in a human colon tumor derived cell line
54. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6
55. Prognostic factors in astrocytomas: Relationship of p53, MDM-2, bcl-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival
56. Apoptosis in astrocytic neoplasms
57. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain
58. PTEN/MMAC1 mutations in primary glioblastomas and short term cultures of malignant gliomas